OXiGENE (OXGN) Says FDA Approved Protocol for Phase 2/3 Study of CA4P for Treatment of Platinum-Resistant Ovarian Cancer
Tweet Send to a Friend
OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
